Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Systemic mastocytosis].

O Fain1, J Stirnemann, V Eclache

  • 1Service de médecine interne, Hôpital Jean Verdier (AP-HP), Université Paris XIII, Bondy. olivier.fain@jvr.ap-hop-paris.fr

Presse Medicale (Paris, France : 1983)
|July 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Atypical Skin Presentation of Adult-Onset Still's Disease With Histological Description: A Case Report.

Journal of cutaneous pathology·2026
Same author

Characteristics and outcomes of patients with pediatric-onset non-mastocytosis mast cell activation disorders: A CEREMAST study.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.

The journal of allergy and clinical immunology. In practice·2025
Same author

Discordance in maximum velocities in the middle cerebral arteries of monochorionic twins: beyond twin anemia-polycythemia sequence.

American journal of obstetrics and gynecology·2025
Same author

Biodegradation study in FBS media of polycaprolactone patch as a potential prenatal treatment for myelomeningocele.

Journal of biomaterials applications·2025
Same author

Postnatal outcome following fetal aortic valvuloplasty for critical aortic stenosis.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2024
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Beyond one-size-fits-all: Personalising health communication to drive real behaviour change.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Systemic mastocytosis involves abnormal mast cell growth, affecting organs like skin and bone. Treatments target mediator release, bone involvement, and mast cell reduction, with new therapies focusing on pathogenic mechanisms.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Systemic mastocytosis (SM) is a rare disorder defined by abnormal mast cell proliferation.
  • SM subtypes include indolent, aggressive forms, and mast cell leukemia, impacting various organs.
  • Clinical symptoms arise from mast cell infiltration and mediator release.

Purpose of the Study:

  • To outline the classification, clinical manifestations, and diagnostic criteria for systemic mastocytosis.
  • To review current therapeutic strategies for managing SM.
  • To highlight emerging targeted treatments based on pathogenic mechanisms.

Main Methods:

  • Diagnosis relies on specific stains (Giemsa, toluidine blue) and immunophenotype analysis (tryptase, CD117).
  • Serum tryptase levels quantify the overall mast cell burden.

Related Experiment Videos

  • Pathogenic mechanisms, including c-kit mutations, are investigated.

    • Main Results:

    • Mast cell proliferation affects skin, bones, digestive tract, liver, spleen, and lymph nodes.
    • Treatment modalities include mediator release inhibitors, bone-modulating agents, and mast cell-reducing therapies.
    • Targeted treatments, such as tyrosine kinase inhibitors, are being developed.

    Conclusions:

    • Systemic mastocytosis requires a multi-faceted approach to treatment, addressing mediator release, organ infiltration, and mast cell burden.
    • Understanding the underlying molecular mechanisms, particularly c-kit mutations, is crucial for developing effective targeted therapies.
    • Advances in targeted treatments offer new hope for patients with systemic mastocytosis.